Acute Leukemia
Acute leukemia is a fast-growing cancer of the blood and bone marrow, leading to an overproduction of immature white blood cells. Symptoms may include fatigue, frequent infections, and easy bruising.
Acute Leukemia: Bleximenib Study
We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have acute leukemia that has not responded to treatment or for which you cannot receive treatment?
- Are you currently pregnant or breastfeeding?
- Have you had any major heart problems in the last 6 months?
- Have you had a fever over 100.5ºF (38ºC) in the last 48 hours?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Bleximenib
Jnj-75276617
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitair Ziekenhuis Gent
Pediatric hemato - Oncology
Ledeberg, Belgium
CHU Besancon
Service Hematologie
Besançon, France
Institut De Cancerologie Strasbourg Europe
Service Hematologie
Eckbolsheim, France
Sponsor: Janssen - Cilag International
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.